Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Weak
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Website
N/ATelephone
61.2.9078.8180
Address
Suite 506, Level 5 50 Clarence Street Sydney, New South Wales (NSW) 2000
Description
Bioxyne Ltd. engages in the research, development, market and distribution of health products. It operates through the following segments: Wholesale, Plant Based, and Direct Sales. The Wholesale segment covers operation in United States of America (USA), and Asia. The Plant Based segment includes manufacturing, commercialization, and distribution of plant-based products. The Direct Sales segment focuses on Australia, and Asia operation. The company was founded in 1998 and is headquartered in Sydney, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.0 - 0.05
Trade Value (12mth)
AU$12,666.00
1 week
20%
1 month
9.09%
YTD
-11.11%
1 year
300%
All time high
8.93
EPS 3 yr Growth
762.50%
EBITDA Margin
-15.00%
Operating Cashflow
-$4m
Free Cash Flow Return
-37.00%
ROIC
-133.10%
Interest Coverage
N/A
Quick Ratio
1.20
Shares on Issue (Fully Dilluted)
2096m
HALO Sector
Industrials
Next Company Report Date
N/A
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
30 April 25 |
Invitation to Investor Webinar 1 May 2025 at 4PM AEST
×
Invitation to Investor Webinar 1 May 2025 at 4PM AEST |
28 April 25 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
07 April 25 |
Notification regarding unquoted securities - BXN
×
Notification regarding unquoted securities - BXN |
07 April 25 |
Notification regarding unquoted securities - BXN
×
Notification regarding unquoted securities - BXN |
07 April 25 |
Notification regarding unquoted securities - BXN
×
Notification regarding unquoted securities - BXN |
03 April 25 |
BXN Signs Exclusive $7m Manufacturing and Supply Agreement
×
BXN Signs Exclusive $7m Manufacturing and Supply Agreement |
03 April 25 |
Prof Michael Barnes MD, FRCP Joins BXN Advisory Board
×
Prof Michael Barnes MD, FRCP Joins BXN Advisory Board |
27 March 25 |
Application for quotation of securities - BXN
×
Application for quotation of securities - BXN |
27 March 25 |
Cleansing Notice
×
Cleansing Notice |
21 March 25 |
Bioxyne Raises A$3 million in Capital Raise
×
Bioxyne Raises A$3 million in Capital Raise |
21 March 25 |
Proposed issue of securities - BXN
×
Proposed issue of securities - BXN |
21 March 25 |
Proposed issue of securities - BXN
×
Proposed issue of securities - BXN |
21 March 25 |
Proposed issue of securities - BXN
×
Proposed issue of securities - BXN |
19 March 25 |
Pause in Trading
×
Pause in Trading |
19 March 25 |
Trading Halt
×
Trading Halt |
04 March 25 |
Bioxyne Investor Webinar 5 March
×
Bioxyne Investor Webinar 5 March |
28 February 25 |
Half Yearly Report and Accounts
×
Half Yearly Report and Accounts |
28 February 25 |
BXN H1 FY25 Results Presentation
×
BXN H1 FY25 Results Presentation |
28 January 25 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
28 January 25 |
Quarterly Activities Report December 2024 Revised
×
Quarterly Activities Report December 2024 Revised |
23 January 25 |
Revenue Guidance
×
Revenue Guidance |
14 January 25 |
Addendum to Presentation dated 18 November 2024
×
Addendum to Presentation dated 18 November 2024 |
19 December 24 |
Notification regarding unquoted securities - BXN
×
Notification regarding unquoted securities - BXN |
19 December 24 |
Notification of cessation of securities - BXN
×
Notification of cessation of securities - BXN |
19 December 24 |
Notification regarding unquoted securities - BXN
×
Notification regarding unquoted securities - BXN |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.